Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
NCT ID: NCT00239330
Last Updated: 2010-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
824 participants
INTERVENTIONAL
2003-06-30
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosuvastatin
Atorvastatin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary hypercholesterolaemia with CV risk \> 20% (as defined in European Guidelines ) and/or type II diabetes and/or a history of CHD or other established atherosclerotic disease. Subjects may be lipid-lowering therapy naïve or have been treated for min. 4 weeks with a 'start' dose of any lipid-lowering therapy, which was ineffective.
* Naïve subjects must have completed 12-weeks dietary counselling before this visit.
* Serious or unstable medical condition
* Statin contraindication
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Vandenhoven, MD
Role: STUDY_DIRECTOR
AstraZeneca NV/SA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Antwerp, , Belgium
Research Site
Arlon, , Belgium
Research Site
Assebroek, , Belgium
Research Site
Ath, , Belgium
Research Site
Aye, , Belgium
Research Site
Bastogne, , Belgium
Research Site
Baudour, , Belgium
Research Site
Borgerhout, , Belgium
Research Site
Bornem, , Belgium
Research Site
Bouge, , Belgium
Research Site
Bruges, , Belgium
Research Site
Brussels, , Belgium
Research Site
Charleroi, , Belgium
Research Site
Dendermonde, , Belgium
Research Site
Frameries, , Belgium
Research Site
Ghent, , Belgium
Research Site
Hasselt, , Belgium
Research Site
Havré, , Belgium
Research Site
Kortenberg, , Belgium
Research Site
Leuven, , Belgium
Research Site
Mol, , Belgium
Research Site
Namur, , Belgium
Research Site
Ostend, , Belgium
Research Site
Roeselare, , Belgium
Research Site
Schoten, , Belgium
Research Site
Sint-Agatha-Berchem, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DISCOVERY
Identifier Type: -
Identifier Source: secondary_id
D3560L00011
Identifier Type: -
Identifier Source: org_study_id